Abstract
Abstract Background Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multi...
Cite
CITATION STYLE
APA
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., … Kochenderfer, J. N. (2019). Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 380(18), 1726–1737. https://doi.org/10.1056/nejmoa1817226
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free